Alligator Bioscience Q3 loss widens 36% year on year to SEK 16.67 million

Bitget2026/10/22 06:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alligator Bioscience’s third-quarter loss widened 36% year over year to SEK 16.67 million.
Net sales fell 49% year over year to SEK 237,000.
A rights issue raised SEK 58.8 million before issue costs; SEK 19 million in bridge loans were repaid.
Financing remains unsecured for the coming 12 months, raising material uncertainty over the ability to continue as a going concern.
Independent mitazalimab development was discontinued to refocus operations on the financial interest in HLX22, currently in global Phase 3 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alligator Bioscience Q3 loss widens 36% year on year to SEK 16.67 million

You may also like

Crypto prices